Ge Long Hui A P P·2025-12-08 08:04Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its product, Amisulpride Orally Disintegrating Tablets, has been successfully included in the National Medical Insurance Directory, effective January 1, 2026, following negotiations with the National Healthcare Security Administration and the Ministry of Human Resources and Social Security [1] Group 1 - The National Medical Insurance Directory for 2025 was published on December 7, 2025, by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security [1] - The Amisulpride Orally Disintegrating Tablets are a modified formulation of the original Amisulpride Tablets launched by Sanofi in France in 1986, used for treating adult schizophrenia [1] - Shanghai Pharmaceuticals' subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., became the marketing authorization holder for Amisulpride Orally Disintegrating Tablets after approval from the National Medical Products Administration in October 2025 [1]